Paper · 42957732

Structural mechanisms underlying resistance to Switch-II pocket inhibitors in KRAS.

Whitley MJ and 13 others. Nat Commun, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Structural mechanisms underlying resistance to Switch-II pocket inhibitors in KRAS. Papers, record 42957732. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42957732

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Structural mechanisms underlying resistance to Switch-II pocket inhibitors in KRAS.
Journal: Nat Commun
Year: 2026
Publication types: Journal Article
PubMed: https://pubmed.ncbi.nlm.nih.gov/42957732/
DOI: https://doi.org/10.1038/s41467-026-78133-4
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13720030/
The journal: https://conductscience.org/library/journal-index/101528555
Revised in PubMed: 2026-11-01

Source PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Whitley MJ	Matthew J	https://orcid.org/0000-0001-8830-7514
2	Dyba M	Marcin	https://orcid.org/0000-0001-6311-6877
3	Chakrabarti M	Mayukh	https://orcid.org/0000-0003-2653-9728
4	Smith BP	Brian P
5	Chan AH	Albert H
6	Denson JP	John-Paul
7	Messing SA	Simon A	https://orcid.org/0000-0001-8991-2097
8	Lin K	Ken
9	Cornilescu G	Gabriel	https://orcid.org/0000-0002-1204-8904
10	Balius TE	Trent E	https://orcid.org/0000-0002-6811-4667

1 to 10 of 14Source PubMed

See all 14 authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Proto-Oncogene Proteins p21(ras)	Major topic
Drug Resistance, Neoplasm	Major topic
Protein Kinase Inhibitors	Major topic
Humans
Mutation
Protein Binding
Binding Sites
Models, Molecular
Protein Conformation
Cell Line, Tumor

Source PubMed

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
P30 GM133893	NIGMS NIH HHS	United States	P30GM133893	PubMed	NIH RePORTER
75N91019D00024	U.S. Department of Health & Human Services \| NIH \| National Cancer Institute (NCI)			PubMed	PubMed
P30 GM133894	NIGMS NIH HHS	United States	P30GM133894	PubMed	NIH RePORTER
P30 GM124165	NIGMS NIH HHS	United States	P30GM124165	PubMed	NIH RePORTER
75N91019D00024	NIH HHS	United States		PubMed	PubMed
S10 OD021527	NIH HHS	United States	S10OD021527	PubMed	NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References77

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	31,324,887	Structures of N-terminally processed KRAS provide insight into the role of N-acetylation.	Sci Rep	2019	https://conductscience.org/library/papers/31324887	PubMed
2	25,477,226	SEDPHAT--a platform for global ITC analysis and global multi-method analysis of molecular interactions.	Methods	2015	https://conductscience.org/library/papers/25477226	PubMed
3	37,258,666	Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.	Nature	2023	https://conductscience.org/library/papers/37258666	PubMed
4	39,283,696	Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96.	ACS Chem Biol	2024	https://conductscience.org/library/papers/39283696	PubMed
5	37,611,121	Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.	N Engl J Med	2023	https://conductscience.org/library/papers/37611121	PubMed
6	39,681,152	Improvements in large-scale production of tobacco etch virus protease.	Protein Expr Purif	2025	https://conductscience.org/library/papers/39681152	PubMed
7	39,788,953	Structural insights into isoform-specific RAS-PI3Kα interactions and the role of RAS in PI3Kα activation.	Nat Commun	2025	https://conductscience.org/library/papers/39788953	PubMed
8	32,250,617	Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.	J Med Chem	2020	https://conductscience.org/library/papers/32250617	PubMed
9	9,917,408	Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation.	J Mol Biol	1999	https://conductscience.org/library/papers/9917408	PubMed
10	38,756,650	KRAS G12C inhibitor combination therapies: current evidence and challenge.	Front Oncol	2024	https://conductscience.org/library/papers/38756650	PubMed

1 to 10 of 77

See all 77 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42957732

GET https://conductscience.org/api/papers/v1/42957732/references?page=2

API reference For AI assistants